<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="429">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 10, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02955706</url>
  </required_header>
  <id_info>
    <org_study_id>NCT_ADC_IV</org_study_id>
    <nct_id>NCT02955706</nct_id>
  </id_info>
  <brief_title>Assessment the Efficacy of Acetyl-L-carnitine in Patient With Alzheimer's Disease</brief_title>
  <official_title>A Multicenter, Randomized, Double-blind, Placebo-controlled Clinical Trial to Assess the Efficacy of Acetyl-L-carnitine in Patient With Alzheimer's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dong-A ST Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dong-A ST Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      clinical trial to assess the efficacy of Acetyl-L-carnitine&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A multicenter, randomized, double-blind, placebo-controlled clinical trial to assess the&#xD;
      efficacy of Acetyl-L-carnitine in patient with Alzheimer's disease&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 1, 2016</start_date>
  <completion_date type="Actual">January 25, 2019</completion_date>
  <primary_completion_date type="Actual">September 29, 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>ADAS-cog</measure>
    <time_frame>24week</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>K-MMSE</measure>
    <time_frame>12week, 24week</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">265</enrollment>
  <condition>Alzheimer Disease</condition>
  <arm_group>
    <arm_group_label>Active</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Acetyl-L-carnitine (DongA ST)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo of Acetyl-L-carnitine (DongA ST)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acetyl-L-Carnitine</intervention_name>
    <description>TID</description>
    <arm_group_label>Active</arm_group_label>
    <other_name>Nicetile</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo of Acetyl-L-Carnitine</intervention_name>
    <description>TID</description>
    <arm_group_label>placebo</arm_group_label>
    <other_name>Placebo of Nicetile</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  More than 50 Years&#xD;
&#xD;
          -  probable Alzheimer disease according to DSM-IV and NINCDS-ADRDA standard&#xD;
&#xD;
          -  12≤K-MMSE(screening)≤26&#xD;
&#xD;
          -  be able to perform examinations&#xD;
&#xD;
          -  Patient taking donepezil(5mg or 10mg/day) more than 3 months&#xD;
&#xD;
          -  be able to visit to hospital with caregiver&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  possible or probable or definite vascular dementia according to NINDS-AIREN standard&#xD;
&#xD;
          -  CNS disease(Cerebrovascular diseases, Epilepsy etc) to cause dementia&#xD;
&#xD;
          -  Illiteracy&#xD;
&#xD;
          -  Patient taking galantamine, memantine, rivastigmine within three months&#xD;
&#xD;
          -  Patient taking brain enhancer, thyroid hormone within 4 weeks&#xD;
&#xD;
          -  Patient taking Central nervous system stimulant, Antipsychotic agent, anticholinergic&#xD;
             agent within 2 weeks&#xD;
&#xD;
          -  at screenig blood test: AST, ALT≥ 3 X upper limit of normal range or Hb≤8g/dL or&#xD;
             platelet&lt;100,000/mm3 or Serum creatinine ≥ 3 X upper limit of normal range&#xD;
&#xD;
          -  Abnormal result of Vit.B12, Syphilis serology, TSH&#xD;
&#xD;
          -  Severe Depression, Schizophrenia, Alcoholism, Drug addiction&#xD;
&#xD;
          -  Parkinson's disease (need to drug therapy)&#xD;
&#xD;
          -  Angina, Myocardial infarction, ischemia within six months&#xD;
&#xD;
          -  Head injury with sense of loss within six months&#xD;
&#xD;
          -  Patient taking other IP within three months&#xD;
&#xD;
          -  Hypersensitivity to IP&#xD;
&#xD;
          -  Sever Hearing problems or Visual impairment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Seol Hee Han, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Konkuk University Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Konkuk university medical center</name>
      <address>
        <city>Seoul</city>
        <zip>KS013</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>November 2, 2016</study_first_submitted>
  <study_first_submitted_qc>November 2, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 4, 2016</study_first_posted>
  <last_update_submitted>April 13, 2021</last_update_submitted>
  <last_update_submitted_qc>April 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetylcarnitine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

